In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This cutting-edge approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation of the transthyretin […]
Finding a needle in the haystack: identifying actionable biomarkers from the plasma proteome
View
